## 







## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 



## 



## 

|||||2022|2021|
|---|---|---|---|---|---|
|||||Unrestricted|Total|
|||||fund|funds|
||||Notes|E|f|
|INCOME AND ENDOWMENTS||FROM||||
|Investment<br>income||||26,722|25,165|
|EXPENDITURE ON||||||
|Charitable activities||||||
|General donations to other charitable||||||
|causes||||13,190|38,000|
|Other||||2,309|930|
|Total||||15,499|38,930|
|Net gains on investments||||7,068|215,450|
|NET INCOME||||18,291|201,685|
|RECONCILIATION|OF FUNDS|||||
|Total funds brought|forward|||1,010,458|808,773|
|TOTAL FUNDS CARRIED FORWARD||||1,028,749|1,010,458|





## 

## 

|||Unrestricted|Total|
|---|---|---|---|
|||fund|funds|
||Notes|6||
|FIXEDASSETS||||
|Investments||1,019,136|1,012,362|
|CURRENT ASSETS||||
|Cash at bank||10,302|8,786|
|CREDITORS||||
|Amounts<br>falling due within one year||(689)|(10,690)|
|NET CURRENT ASSETS||9,613|(1,904)|
|TOTAL ASSETSLESSCURRENT||||
|LIABILITIES||1,028,749|1,010,458|
|NET ASSETS||1,028,749|1,010,458|
|FUNDS||||
|Unrestricted<br>funds||1,028,749|1,010,458|
|TOTAL FUNDS||1,028,749|1,010,458|





## 

## 

## 

## 

## 




## 

## 

## 

|GRANTS PAYAB|LE||||
|---|---|---|---|---|
||||2022|2021|
||||E|E|
|General donations|to other charitable causes||12,500|38,000|
|The total grants paid to institutions||during the year was as|||
|follows:|||||
||||2022|2021|
||||6|5|
|Motor Neurone||||2,000|
|Samaritans||||2,000|
|Wye Hops||||10,000|
|Young Classical Artists Trust||||10,000|
|Read Easy<br>MenCap|||12,500|12,500<br>1,500|
||||12,500|38,000|



## 

## 

## 

|There were<br>no<br>trustees'<br>expenses<br>paid<br>for the yea<br>5 April 2021.<br>FIXEDASSETINVESTMENTS|r ended<br>5 April<br>2022 nor for the year<br>ende|
|---|---|
||Listed|
||investments|
||F|
|MARKET VALUE||
|At 6April 2021|1,012,362|
|Additions|232,243|
|Disposals|(57,080)|
|Revaluations|(168,389)|
|At 5 April 2022|1,019,136|
|NET BOOK VALUE||
|At 5 April 2022|1,019,136|
|At 5 April 2021|1,012,362|





## 


## 

||||||||||||5.4.22||5.4.21|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
||||||||||||6||f|
|Historicai cost|(All|UK)|||||||||318,195||143,032|
|The following|holdings|||each|comprise|more|than|5'Yo of the|market|value|of the investment||portfolio|
|and are considered|||by|the trustees to||be individually||material.||||||
||||||||||Market|||||
|Holding|||||||||Value||5.4.22|5.4.21||
||||||||||6||0/|0/||
|Astrazeneca|||||||||54,770||5 40'/o|8.15'/0||
|Caledonia|Invs||||||||53,175||5.24'/o|3.93'/o||
|Royal Dutch Shell||||Transport|||||50,756||5.01'/o|8.41'/o||
|M&G Equities||Investment|||Fund||||69,594||6.86'/o|6.87'/o||
|Unilever|||||||||295,651||29.16'/0|34.16'/o||
|JPMorgan|GBLGrowth||||& INC||||51,129||5.04'/o|||
|LXI Rebit PLC|||||||||53,876||5 31o/o|||
|JPMorgan|GLBCore Assets LTD||||||||51,982||5.13'/o|||
|Cost or valuation||at 5 April 2022 is represented|||||by:|||||||
||||||||||||||Listed|
|||||||||||||investment||
||||||||||||||6|
|Valuation<br>in 2021||||||||||||1,012,362||
|Valuation<br>in 2022|||||||||||||6,774|
|||||||||||||1,019,136||
|CREDITORS:|AMOUNTS FALLING DUE WITHIN|||||||ONE YEAR||||||
||||||||||||2022||2021|
||||||||||||6||6|
|Trade creditors|||||||||||||10,000|
|Other creditors|||||||||||689||690|
||||||||||||689||10,690|





## 



## 

||||2022<br>E|2021f|
|---|---|---|---|---|
|INCOME AND ENDOWMENTS|||||
|Investment<br>income|||||
|Dividends receivable|||25,875|25,165|
|Deposit account interest|||847||
||||26,722|25,165|
|Total incoming resources|||26,722|25,165|
|EXPENDITURE|||||
|Charitable<br>activities|||||
|Grants to institutions|||12,500|38,000|
|Supportcosts|||||
|Management|||||
|Administration<br>fees|||960|240|
|Accountancy fees|||360|400|
||||1,320|640|
|Governance costs|||||
|Sundries|||1,331||
|Independent<br>examiner's fees|||348|290|
||||1,679|290|
|Total resources expended|||15,499|38,930|
|Net income/(expenditure)||before gains|||
|and losses|||11,223|(13,765)|
|Realised recognised gains and losses|||||
|Realised gains/(losses)|on|fixed asset|||
|investments|||175,457||
|Net income/(expenditure)|||186,680|(13,765)|